Xbrane Biopharma AB Financial Overview
Xbrane Biopharma AB's market cap is currently kr221.75M. The company's EPS TTM is kr-1.17; its P/E ratio is 1.20; Xbrane Biopharma AB is scheduled to report earnings on October 24, 2025, and the estimated EPS forecast is kr-1.49. See an overview of income statement, balance sheet, and cash flow financials.
